Abstract 1066
Background
Ostomy patients (pts) can develop some complications treated by nurse enterostomista, such as skin alterations and early or late complications. Stomal complications have a varying incidence (from 25 to 35%). Neoplastic ostomy pts often undergo chemo (CT) and/or radiation therapy (RT), also in association, and they can show stomal lesions or complications with an important impact on their daily life. Stomal side effects induced by CT-RT represent an important problem for pts, who need for a competent and organized support in order to be able to cope with them. In the literature, few studies report the care and assistance to the stomized pts.The aim of this study was to detect precociously stomal complications in order to treat them early, improving pts quality of life, and to demonstrate that these complications are more frequent in pts treated with CT and/or RT.
Methods
From 11.2017 to 5.2018 60 cancer ostomy pts were surgically treated for different types of cancers at our institution. 29 out 60 have been also treated with CT and/or RT at Medical Oncology Dept. 73% were male and 27% female. We evaluated stomal complications and classified them according to SACS scale. Our aim was to demonstrate a higher percentage of stomal complications in pts CT and/or RT treated vs untreated pts.
Results
At a median follow-up of 4 months, 29 out 60 ostomy pts were treated with CT, 2 with CT-RT, the remaining 29 underwent follow-up. 15 out 29 pts (51%) treated with CT and/or RT showed stomal complications: 14 with SACS - L1 skin alterations (redness without loss of substance) and 1 with SACS-L2 lesion (with loss of substance). Patients undergoing follow-up didn’t have any stomal complications.
Conclusions
Despite the recognized limitations of our study (small sample size and short median follow-up) we can conclude that there is an increase of complications in ostomy pts treated with CT and/or RT vs untreated pts and that this problem occurs in over half of population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cristoforo Ferrero.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3264 - A novel preclinical model of RAF-independent MEK1 mutant tumors and its treatment with novel ATP competitive MEK inhibitor
Presenter: Luca Hegedus
Session: Poster Display session 3
Resources:
Abstract
4918 - HER2 inhibition in Aggressive Squamous Cell Carcinomas driven by a common MET Sema Domain Polymorphism
Presenter: Nur Afiqah Mohamed Salleh
Session: Poster Display session 3
Resources:
Abstract
2426 - ADAM9 as a target for lung cancer treatment
Presenter: Yuh-pyng Sher
Session: Poster Display session 3
Resources:
Abstract
5537 - Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer
Presenter: Marta Perez Hernandez
Session: Poster Display session 3
Resources:
Abstract
1597 - Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer
Presenter: Hsing-pang Hsieh
Session: Poster Display session 3
Resources:
Abstract
3543 - Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status – putative targets
Presenter: Vilde Haakensen
Session: Poster Display session 3
Resources:
Abstract
4111 - Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer
Presenter: Asuka Kawachi
Session: Poster Display session 3
Resources:
Abstract
4559 - Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in Patients with RET-altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer
Presenter: Giuseppe Curigliano
Session: Poster Display session 3
Resources:
Abstract
2501 - Triple MET/SRC/PIM inhibition in MET addicted tumors
Presenter: Ilaria Attili
Session: Poster Display session 3
Resources:
Abstract
5655 - Bioactivation of napabucasin triggers reactive oxygen species–mediated cancer cell death
Presenter: Fieke Froeling
Session: Poster Display session 3
Resources:
Abstract